Key facts
- This page summarizes Kumar Budur's Form 3 filing for Harmony Biosciences Holdings, Inc. (HRMY).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Jan 2024, 16:58.
Kumar Budur - 01 May 2023 Form 3 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- HRMY
- Reported as of
- 01 May 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 26 Jan 2024, 16:58:43 UTC
- Next SEC filing
- 26 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christian Ulrich, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kumar Budur filed Form 3 for Harmony Biosciences Holdings, Inc. (HRMY) on 26 Jan 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HRMY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,005
- Date
- 01 May 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRMY
holding
Derivative
Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $49.27
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests with respect to 50% of the underlying shares on March 21, 2024, with the remaining shares vesting in twenty-four equal monthly installments beginning on April 21, 2024, subject to the Reporting Person's continued service through each applicable vesting date.